RE: Akron tie-up20 Oct 2020 08:35
Twas in the placings RNS
Synairgen has signed an agreement with Akron Biotechnology, a leading provider of cGMP-compliant solutions to support the development of advanced therapies, to supply SNG001 drug substance in order to meet expected clinical and commercial demand for the drug. Akron have the capacity to scale up production of SNG001, with the aim of producing approximately 100,000 treatment courses per month in 2021. Lead times mean that the investment for this scale-up is required now. The SGO018 Phase III trial will commence using Rentschler-derived drug substance, with the Akron-derived drug substance intended to be introduced during the trial in preparation for commercial supply.